Your browser doesn't support javascript.
loading
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
Krepler, Clemens; Xiao, Min; Sproesser, Katrin; Brafford, Patricia A; Shannan, Batool; Beqiri, Marilda; Liu, Qin; Xu, Wei; Garman, Bradley; Nathanson, Katherine L; Xu, Xiaowei; Karakousis, Giorgos C; Mills, Gordon B; Lu, Yiling; Ahmed, Tamer A; Poulikakos, Poulikos I; Caponigro, Giordano; Boehm, Markus; Peters, Malte; Schuchter, Lynn M; Weeraratna, Ashani T; Herlyn, Meenhard.
Afiliação
  • Krepler C; Molecular and Cellular Oncogenesis Program, Tumor Microenvironment and Metastasis Program, and Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania. ckrepler@Wistar.org.
  • Xiao M; Molecular and Cellular Oncogenesis Program, Tumor Microenvironment and Metastasis Program, and Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania.
  • Sproesser K; Molecular and Cellular Oncogenesis Program, Tumor Microenvironment and Metastasis Program, and Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania.
  • Brafford PA; Molecular and Cellular Oncogenesis Program, Tumor Microenvironment and Metastasis Program, and Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania.
  • Shannan B; Molecular and Cellular Oncogenesis Program, Tumor Microenvironment and Metastasis Program, and Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania.
  • Beqiri M; Molecular and Cellular Oncogenesis Program, Tumor Microenvironment and Metastasis Program, and Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania.
  • Liu Q; Molecular and Cellular Oncogenesis Program, Tumor Microenvironment and Metastasis Program, and Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania.
  • Xu W; University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania.
  • Garman B; University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania.
  • Nathanson KL; University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania.
  • Xu X; University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania.
  • Karakousis GC; University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania.
  • Mills GB; University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lu Y; University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ahmed TA; Icahn School of Medicine at Mount Sinai, New York, New York.
  • Poulikakos PI; Icahn School of Medicine at Mount Sinai, New York, New York.
  • Caponigro G; Novartis Oncology Translational Medicine, Cambridge, Massachusetts.
  • Boehm M; Novartis Oncology Translational Medicine, Cambridge, Massachusetts.
  • Peters M; Novartis Oncology Translational Medicine, Cambridge, Massachusetts.
  • Schuchter LM; University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania.
  • Weeraratna AT; Molecular and Cellular Oncogenesis Program, Tumor Microenvironment and Metastasis Program, and Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania.
  • Herlyn M; Molecular and Cellular Oncogenesis Program, Tumor Microenvironment and Metastasis Program, and Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania.
Clin Cancer Res ; 22(7): 1592-602, 2016 Apr 01.
Article em En | MEDLINE | ID: mdl-26673799
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Resistencia a Medicamentos Antineoplásicos / Proteínas Proto-Oncogênicas B-raf / Inibidores de Proteínas Quinases / Avaliação Pré-Clínica de Medicamentos / Melanoma / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Resistencia a Medicamentos Antineoplásicos / Proteínas Proto-Oncogênicas B-raf / Inibidores de Proteínas Quinases / Avaliação Pré-Clínica de Medicamentos / Melanoma / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article